Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

9 clinical studies listed.

Filters:

Leiomyoma

Tundra lists 9 Leiomyoma clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06143631

Prescription of Letrozole for Uterine Myoma

The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.

Gender: FEMALE

Ages: 21 Years - 53 Years

Updated: 2026-10-06

4 states

Leiomyoma, Uterine
Leiomyoma
Fibroid
+1
COMPLETED

NCT04145518

Mechanistic Characterization of Uterine Pain

There are limited treatment options for management of dysmenorrhea, and the physiological processes they affect are not completely understood. For example, NSAIDs are effective in reducing menstrual pain in some women by inhibition of prostaglandin synthesis, but whether those effects are mediated by affecting contractility, perfusion, or hypoxemia is unknown. Understanding how these drugs relieve menstrual pain (and why they fail) would be of substantial clinical significance. Given the foregoing, Two Specific Aims are proposed: Aim #1: Characterize menstrual pain phenotypes associated with impairments in myometrial activity, perfusion, and/or oxygenation. Continuous MRI scans of the uterus will be performed with simultaneous measurement of self-reported pain in healthy women and those experiencing menstrual pain. The investigators will include cohorts of women with imaging diagnosed leiomyoma and surgically-confirmed endometriosis to evaluate the contribution of structurally identifiable factors. Based on preliminary data, the investigators anticipate finding four phenotypes with menstrual pain related to: 1) myometrial activity, 2) inadequate perfusion and/or oxygenation, 3) a combination of phenotypes 1 \& 2, and 4) a non-uterine source. Aim #2: Evaluate the effects of naproxen on myometrial activity, perfusion, and/or oxygenation with respect to pain relief. In women with primary dysmenorrhea, the investigators will acquire pelvic MRI scans and evaluate self-reported menstrual cramping pain before and after administration of randomized naproxen or placebo. Naproxen could principally affect one or more potential sources of uterine pain such as myometrial activity, perfusion, and/or oxygenation. The investigators will corroborate preliminary data findings, which suggest menstrual phenotypes with myometrial activity will be more likely to respond. Conversely, Aim 2 will also elucidate the mechanisms responsible for inadequate pain relief from naproxen. Bioavailability of naproxen levels and other molecules associated with NSAID-resistance will be evaluated from the serum of participants after taking naproxen using HPLC-MS.

Gender: FEMALE

Ages: 18 Years - 45 Years

Updated: 2026-09-23

1 state

Dysmenorrhea (Disorder)
Dysmenorrhea Primary
Dysmenorrhea Secondary
+3
NOT YET RECRUITING

NCT07746349

Terlipressin vs Placebo to Reduce Bleeding in Fibroid Surgery

A myomectomy is a surgery to remove noncancerous growths (fibroids) from the uterus while keeping the uterus in place. This surgery can cause significant blood loss. Terlipressin is a medicine that narrows blood vessels and may help reduce bleeding. This study will test whether injecting a diluted terlipressin solution under the outer covering of the fibroid, before it is removed, reduces the amount of blood lost during surgery, compared to an inactive solution (placebo). Women scheduled for myomectomy will be randomly assigned to receive either terlipressin or placebo. Neither the patients nor the surgical team will know which one was given until the study is finished. The main question this study will answer is how much blood is lost during surgery in each group.

Gender: FEMALE

Updated: 2026-08-05

Uterine Fibroids (Leiomyoma)
Uterine Myoma
Leiomyoma
ACTIVE NOT RECRUITING

NCT03400826

Effects of Simvastatin on Uterine Leiomyoma Size

The study aims to study the effect of simvastatin on the size of uterine fibroids.

Gender: FEMALE

Ages: 18 Years - 55 Years

Updated: 2026-07-21

1 state

Fibroid Uterus
Fibroid Tumor
Leiomyoma
+2
WITHDRAWN

NCT05538689

Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

In this project, the proposition is that the use of daily dosed Myfembree ( a combination of relugolix with estradiol and norethindrone acetate), FDA-approved medication to treat heavy menses fibroid-related symptoms, has the potential to delay the recurrence of fibroid symptoms, prolong the improved quality of life and delay the need for re-intervention after uterine sparing surgery versus the routine standard of care.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2026-06-05

2 states

Metrorrhagia
Pelvic Pain
Menorrhagia
+1
RECRUITING

NCT06135870

Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)

The investigators are evaluating the role of senescent cells in uterine fibroids.

Gender: FEMALE

Ages: 18 Years - 55 Years

Updated: 2025-12-11

1 state

Fibroid
Leiomyoma
RECRUITING

NCT07078682

An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms

This is a 24-week, single-arm, open-label, virtual study evaluating the effects of Elix Cycle Balance and Elix Daily Harmony on uterine fibroid-related symptoms and quality of life in 42 participants. Participants will self-administer the investigational herbal supplements daily and complete validated questionnaires at scheduled timepoints to assess symptom severity and quality of life.

Gender: FEMALE

Ages: 20 Years - 45 Years

Updated: 2025-09-12

1 state

Uterine Fibroids
Leiomyoma
Menstrual Pain
NOT YET RECRUITING

NCT07106411

CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study

The investigators conduct a prospective, multicenter diagnostic trial primarily aimed at evaluating the value of contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS) in differentiating gastrointestinal stromal tumors (GISTs) from leiomyomas, as well as its predictive utility in the risk stratification of GISTs.

Gender: All

Ages: 18 Years - 85 Years

Updated: 2025-08-06

1 state

Submucosal Tumor
Gastrointestinal Stromal Tumor (GIST)
Leiomyoma
RECRUITING

NCT07078136

Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis

This study develops a multimodal AI model using endoscopic ultrasound, white-light endoscopy, and clinical information to support the diagnosis of upper GI mesenchymal tumors and the risk stratification of gastric GISTs.

Gender: All

Ages: 18 Years - Any

Updated: 2025-07-31

1 state

Submucosal Tumor
Gastrointestinal Stromal Tumor (GIST)
Leiomyoma
+1